ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

9557	Companies
188741	Keywords
120497	Articles
100741	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 10/16/2025 at 20:57, 2 months 2 days ago

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science provides initial Phase 1 data for combination of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia. Promising results incl. 100% disease control rate and 100% response rate

AB Science AB8939 Phase 1 Data AML Venetoclax
PRESS RELEASE

published on 10/16/2025 at 20:57, 2 months 2 days ago

AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute
AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute. Des résultats prometteurs pour les patients atteints de LMA

Traitement AB Science AB8939 Leucémie Myéloïde Aiguë Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 2 months 5 days ago

AB Science publie des données initiales prometteuses issues d'une étude sur la LAM

Essai Clinique AB Science AB8939 Traitement De La LAM Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 2 months 5 days ago

AB Science Reports Promising Initial Data from AML Study

Clinical Trial AML Treatment AB Science AB8939 Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 2 months 5 days ago

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
AB Science releases positive initial data on combination treatment of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia (AML), showing promising results in patients with unfavorable genetic profiles. Virtual conference scheduled with renowned experts in AML

Virtual Conference AB Science AB8939 AML Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 2 months 5 days ago

AB Science tiendra une conférence virtuelle le jeudi 16 octobre 2025, de 14 h à 15 h CET, afin de faire le point sur l'étude de phase 1 avec AB8939
AB Science publie les premières données de la combinaison de AB8939 avec Vénétoclax dans le traitement de la LMA, avec des résultats très encourageants. Une conférence virtuelle est prévue le 16 octobre 2025

Conférence Virtuelle AB Science AB8939 Venetoclax LMA
PRESS RELEASE

published on 10/10/2025 at 18:17, 2 months 8 days ago

Rapport financier semestriel 2025
BRIEF

published on 08/04/2025 at 08:03, 4 months 15 days ago

AB Science Completes EUR 2.55 Million Private Placement

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF

published on 08/04/2025 at 08:03, 4 months 15 days ago

AB Science finalise un placement privé de 2,55 millions d'euros

Actionnaires Placement Privé Développement Clinique AB Science 2,55 Millions D'euros
PRESS RELEASE

published on 08/04/2025 at 07:58, 4 months 15 days ago

AB Science announces the successful completion of a 2.55 million euros private placement
AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million

Accesswire

Published on 12/19/2025 at 14:40, 15 minutes ago

Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 1 hour 25 minutes ago

Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF
Published on 12/19/2025 at 13:30, 1 hour 25 minutes ago

DataMetrex Announces Closing of Yuzu Payment Processing Solution Acquisition
Published on 12/19/2025 at 13:30, 1 hour 25 minutes ago

Sterling Metals Provides Year End Update to Stakeholders
Published on 12/19/2025 at 13:05, 1 hour 50 minutes ago

Roxmore Resources Begins Trading on the OTCQX Best Market in the United States

View all ACCESSWIRE

EQS Group

Published on 12/19/2025 at 14:39, 15 minutes ago

EQS-Adhoc: Cantourage Group SE expects EBITDA for 2025 to exceed current market expectations based on preliminary figures
Published on 12/19/2025 at 14:05, 49 minutes ago

ETHGas Debuts Ethereum's Blockspace Futures Market with $800m of Commitments and $12m Seed Round Led by Polychain Capital
Published on 12/19/2025 at 14:00, 54 minutes ago

EQS-Adhoc: EVAN Group plc: Delisting of Bond has been resolved
Published on 12/19/2025 at 13:31, 1 hour 23 minutes ago

North Peak Confirms Historic Waste Rock Pile Mineralisation with Sonic Drilling and Completion of 2025 Reverse Circulation Exploration Drilling Program at Prospect Mountain, Nevada
Published on 12/19/2025 at 13:18, 1 hour 36 minutes ago

Gennaker offshore wind farm obtains construction and operations permit

Les Echos

Published on 12/19/2025 at 08:30, 6 hours 25 minutes ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 6 hours 25 minutes ago

Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 7 hours 55 minutes ago

EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 7 hours 55 minutes ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 20 hours 25 minutes ago

Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV

View all LES ECHOS COMFI WIRE